Finally, our data suggest that a combination of STAT3 inhibition with glucose deprivation may represent a valuable therapeutic strategy in cancer, providing a mean to hit fundamental metabolic functions of a wide variety of STAT3-dependent, highly glycolytic tumours more effectively than STAT3 inhibition alone. This evidence concerns the gene STAT3 and neoplasm.